AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:17 2024-06-03 am EDT			5-day change	1st Jan Change
12,346 ^GBX	+1.28%		+2.64%	+16.47%

05:39pm	Global markets live: GSK, Walt Disney, Blackstone, Boeing, Microsoft...
01:24pm	ASTRAZENECA : JP Morgan remains its Buy rating	ZD

ASTRAZENECA : Gets a Neutral rating from Deutsche Bank

May 22, 2024 at 04:25 am EDT

Emmanuel Papadakis from Deutsche Bank retains his Neutral opinion on the stock. The target price continues to be set at GBX 11000.

Latest news about AstraZeneca PLC

Global markets live: GSK, Walt Disney, Blackstone, Boeing, Microsoft...	11:39am
ASTRAZENECA : JP Morgan remains its Buy rating	07:24am	ZD
AstraZeneca: CHMP recommends approval of Tagrisso in the EU	05:35am	CF
AstraZeneca's Tagrisso Reduces Lung Cancer Progression in Phase 3 Trial	05:19am	MT
AstraZeneca: Tagrisso shows promise in lung cancer	04:35am	CF
AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients	04:35am	MT
AstraZeneca: conclusive trial in lung cancer	04:22am	CF
AstraZeneca cancer treatment Tagrisso recommended for approval in EU	04:00am	AN
AstraZeneca: conclusive trial for Enhertu in breast cancer	03:58am	CF
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%	03:54am	MT
AstraZeneca's Tagrisso Secures Recommendation for EU Approval for Advanced Lung Cancer with Chemotherapy	02:32am	MT
AstraZeneca's Imfinzi Lowers Risk of Death in Patients with Limited-stage Small Cell Lung Cancer	12:42am	MT
AstraZeneca Reports Positive Results from Non-small Cell Lung Cancer Drug Trial	12:39am	MT
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug	12:28am	MT
Japan System Techniques Partners City of Takamatsu, AstraZeneca on Education Programs on COPD	11:43pm	MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results	Jun. 02	RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels	Jun. 02	RE
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified	Jun. 02	RE
ASTRAZENECA: SAFETY PROFILE OF ENHERTU WAS CONSISTENT WITH PREV…	Jun. 02	RE
ASTRAZENECA: DATA FROM TRIALS IN HER2-POSITIVE METASTATIC BREAS…	Jun. 02	RE
ASTRAZENECA: ENHERTU SHOWED MEDIAN PROGRESSION-FREE SURVIVAL AF…	Jun. 02	RE
Health Care Stocks Climb On Drug News -- Health Care Roundup	May. 31	DJ
Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal	May. 31	MT
News Highlights: Top Company News of the Day - Friday at 1 PM ET	May. 31	DJ
News Highlights : Top Company News of the Day - Friday at 11 AM ET	May. 31	DJ

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

10:12am - American Society of Clinical Oncology Meeting - Abstract No:8005

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

155.1 USD

Average target price

172 USD

Spread / Average Target

+10.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+16.47%	240B
ELI LILLY AND COMPANY	+42.31%	739B
NOVO NORDISK A/S	+32.34%	598B
JOHNSON & JOHNSON	-5.88%	353B
MERCK & CO., INC.	+17.54%	318B
ABBVIE INC.	+3.25%	285B
NOVARTIS AG	+9.26%	210B
ROCHE HOLDING AG	-5.07%	206B
AMGEN INC.	+7.00%	164B
PFIZER, INC.	+1.63%	162B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Gets a Neutral rating from Deutsche Bank

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals